ESMO 2023 Insights: "A Multicenter, Randomized, Open-Label, Three-Arm, Phase 2/3 GENERATE Study - NabP + Gem vs. Modified FOLFIRINOX or S-IROX in Metastatic or Recurrent Pancreatic Cancer"

327 views
October 27, 2023
0 Comments
Login to view comments. Click here to Login